Clinical trial
A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
NCT05285540 is registered in ClinicalTrials.gov with Design Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
- Lead sponsor
- Design Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 11, 2022
- Completion date
- December 19, 2022
- Enrollment
- 39 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.